Denver, CO, March 31, 2026  AOA Dx, a leader in multi-omics diagnostics focused on improving early cancer detection, announced the appointment of Chris Roberts as Chief Product Officer (CPO). Roberts will lead product strategy, commercialization, and market access efforts as the company advances its ovarian cancer diagnostic platform, AKRIVIS GD™ Test System.

Roberts joins AOA Dx with more than two decades of leadership experience across oncology diagnostics, molecular testing, and precision medicine. He has a proven track record of bringing innovative products from concept through commercialization, with deep expertise navigating FDA and CLIA-regulated environments.

“Chris is exactly the kind of leader we need at this pivotal moment,” said Oriana Papin-Zoghbi, CEO of AOA Dx. “His ability to translate complex science into successful, reimbursed, and widely adopted diagnostic products will be critical as we prepare AKRIVIS GD™ for clinical adoption. He understands not just how to build great products, but how to ensure they reach patients and make a real impact.”

Most recently, Roberts served as Chief Product Officer at Arima Genomics, where he established the Aventa clinical oncology testing service and led product and commercial strategy, product development, reimbursement, and CLIA laboratory operations.

Roberts also held multiple leadership roles at Decipher Biosciences (Veracyte), including Vice President of Corporate Initiatives and Vice President of Marketing, where he led product strategy, marketing, and strategic reimbursement efforts. His work contributed to expanded Medicare coverage, improved payer adoption, and significant growth of the Decipher Prostate test portfolio.

Previously, at Caris Life Sciences, he served as Vice President of Oncology, scaling the molecular profiling business with over 200% CAGR. He began his career in diagnostics leadership roles at Ventana Medical Systems (Roche), where he contributed to the development and commercialization of multiple IVD assays, including companion diagnostics.

At AOA Dx, Roberts will focus on advancing AKRIVIS GD™, the company’s first-in-class multi-omics liquid biopsy designed to detect ovarian cancer earlier and more accurately.

AKRIVIS GD™ introduces a new diagnostic paradigm by combining multiple biological layers, lipids, proteins, and clinical data into a single machine-learning–driven liquid biopsy platform. This approach represents a significant improvement from traditional single-biomarker diagnostics.

Ovarian cancer remains one of the deadliest cancers for women, with nearly 80% of cases diagnosed at advanced stages. Current tools often lack the sensitivity and specificity needed for early detection, leading to delayed diagnoses and unnecessary procedures.

AOA Dx’s platform is designed to address this gap. In peer-reviewed studies, AKRIVIS GD™ has demonstrated:

• • 94.8% sensitivity for early-stage ovarian cancer 
  • 94.4% sensitivity across all stages and subtypes
  • Strong performance across large, clinically diverse patient cohorts 

The test is currently in late-stage product development, with patients enrolled in a pivotal trial across the United States. AOA Dx plans to launch an early access program while pursuing FDA clearance.

“AOA Dx is tackling one of the most important unmet needs in diagnostics. AKRIVIS GD™ has the potential to fundamentally change how ovarian cancer is detected, moving diagnosis earlier, improving clinical decision-making, and ultimately saving lives. I’m excited to join this team and help bring this breakthrough technology to patients and providers.” said Chris Roberts, Chief Product Officer

With Roberts leading product and commercial strategy, AOA Dx is well-positioned to deliver on its mission, providing clinicians with a more accurate, minimally invasive tool to evaluate women presenting with symptoms suggestive of ovarian cancer, improving outcomes for millions of patients each year.